6[7]King AB.Comparison in a coinical setting of efficacy and side effects of three thiazolidines[J].Diavetes Care,2000,23(4):557.
二级参考文献26
1[7]Koev D,Ionescu-Trgoviste C,Rosenthal A,et al.Balaglitazone,a new thiazolidinedione,improves glucose and lipid control in patients with type Ⅱ diabetes[J].Diabetes,2003,52( Suppl 1 ) :530.
2[8]Imoto H,Sugiyama Y,Kimura H,et al. Studies on non-thiazolidinedione antidiabetic agents.2.Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents[J].Chem Pharm Bull,2003,51 ( 2 ): 138.
4[10]Kersey K,Floren LC,Pendleton B,et al.T0903131 ,a selective modulator of PPAR-gamma activity,increases adiponectin levels in healthy subjects[A].In:64th Annu Meet Sci Sess Am Diabetes Assoc[C].2004: 656-P.
5[11]McIntyre JA,Castaner J,Bayes M,et al.Tesaglitazar treatment of type Ⅱ diabetes,treatment of metabolic syndrome,PPAR α /PPAR γ agonist[J].Drugs Fut, 2003,28 ( 10 ): 959.
6[12]Hegarty BD,Furler SM,Oakes N,et al. Peroxisome Proliferator-Activated Receptor(PPAR)activation induces tissue-specific effects on fatty acid uptake and metabolism in vitro-a study using the novel PPAR α/γagonist tesaglitazar[J].Endocrinology,2004,145:3158.
